Retatrutide 4mg: First Titration Step
Retatrutide 4mg is where the triple agonist begins to show its true therapeutic power. In Phase 2 trials, the 4mg dose alone produced an average of 17.5% body weight loss over 48 weeks (Jastreboff et al., NEJM 2023) — more than the maximum dose of semaglutide (Wegovy) typically achieves. For many patients, 4mg may be the right maintenance dose, offering exceptional weight loss with a favorable side effect profile.
Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Always consult a qualified healthcare provider.
What Makes 4mg Special
The 4mg dose is the threshold where all three receptor activations reach clinically meaningful levels. At lower doses, the effects are primarily GLP-1-mediated (appetite suppression). At 4mg, the GIP and glucagon components become significant contributors — you begin to see improved metabolic efficiency and increased energy expenditure that distinguish retatrutide from single-agonist drugs.
Expected Results at 4mg
| Outcome | Retatrutide 4mg | Context |
|---|---|---|
| Avg weight loss (48 wks) | 17.5% | Exceeds semaglutide 2.4mg (~15%) |
| Nausea rate | ~16% | Lower than semaglutide (~44%) |
| Dysesthesia rate | ~6% | Much lower than 12mg (20.9%) |
| Heart rate change | 1-2 bpm | Clinically insignificant |
4mg as a Maintenance Dose
Not everyone needs to escalate to 8mg or 12mg. If 4mg provides sufficient weight loss for your health goals and you are tolerating it well, staying at 4mg is a perfectly valid strategy. The benefit-risk ratio at 4mg is excellent: weight loss exceeding semaglutide with lower side effect rates than any higher dose.
Consider 4mg as your maintenance dose if you have achieved 15%+ weight loss and reached your goal, if side effects at 4mg are minimal and you want to maintain that tolerability, or if your starting BMI was 30-35 and 17.5% loss achieves a healthy weight.
When to Consider Escalating to 8mg
- Weight loss has plateaued at 4mg and your goal is not reached
- You are tolerating 4mg well and want faster/greater results
- Your physician recommends escalation based on clinical assessment
- You have significant remaining excess weight (BMI still above 30)
Begin Treatment Now
Trimi offers compounded semaglutide at $99/month and compounded tirzepatide at $125/month with individualized dose titration. Start losing weight today with proven GLP-1 medications. Get started with Trimi.
Frequently Asked Questions
Is retatrutide 4mg enough for weight loss?
Yes. The 4mg dose produces 17.5% average weight loss — more than any single-agonist GLP-1 medication. For many patients, this is sufficient to achieve health goals.
How much weight will I lose per month at 4mg?
Approximately 1.5% of body weight per month at 4mg. For a 250-pound person, this translates to roughly 3-4 lbs per month.
Are side effects much lower at 4mg than 12mg?
Yes. Nausea (16% vs 26%), dysesthesia (6% vs 20.9%), and heart rate changes (1-2 vs 2-4 bpm) are all substantially lower at 4mg. The trade-off is less total weight loss (17.5% vs 24.2%).
Can I split my dose instead of escalating?
Retatrutide is a once-weekly injection and should not be split. If you want to stay at 4mg, simply maintain that dose without escalating.
More on Retatrutide
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).